Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy

Immune checkpoint inhibitors (ICIs) have greatly improved the survival of patients with advanced melanoma and several other types of cancer. Due to their mechanism of action, ICIs can cause immune-related adverse events (irAEs) that mostly involve the skin, the gastrointestinal tract and the endocri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2017-09, Vol.83, p.28-31
Hauptverfasser:	Boisseau, W., Touat, M., Berzero, G., Savatovsky, J., Marabelle, A., Touitou, V., Ricard, D., Malouf, G., Psimaras, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Corticoids Corticosteroids Drug Substitution Endocrine system Female Gastrointestinal tract Humans Immune checkpoint inhibitors Immunotherapy Ipilimumab - adverse effects Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Melanoma Meningitis - chemically induced Meningitis - complications Metastases Monoclonal antibodies Morbidity Neoplasm Metastasis Neuritis Optic Nerve Diseases - chemically induced Optic Nerve Diseases - complications Optic neuritis Optic neuropathy Radiculopathy - chemically induced Radiculopathy - complications Renal cell carcinoma Skin Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Immune checkpoint inhibitors (ICIs) have greatly improved the survival of patients with advanced melanoma and several other types of cancer. Due to their mechanism of action, ICIs can cause immune-related adverse events (irAEs) that mostly involve the skin, the gastrointestinal tract and the endocrine system. Neurological irAEs are rare (
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2017.05.036